Health Care & Life Sciences » Biotechnology | Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
25,548.00
65,358.00
59,119.00
69,892.00
43,011.00
94,387
SG&A Expense
62,991.00
118,124.00
174,477.00
265,169.00
357,373.00
448,297
EBIT
38,883.00
54,133.00
118,700.00
200,985.00
320,794.00
362,479
Pretax Income
38,828.00
53,930.00
117,732.00
198,471.00
314,670.00
346,028
Income Tax
579.00
426.00
-
-
-
-
Consolidated Net Income
39,407.00
53,504.00
117,732.00
198,471.00
314,670.00
346,028
Net Income
39,407.00
53,504.00
117,732.00
198,471.00
314,670.00
346,028
Net Income After Extraordinaries
39,407.00
53,504.00
117,732.00
198,471.00
314,670.00
346,028
Net Income Available to Common
43,569.00
53,504.00
117,732.00
198,471.00
314,670.00
346,028
EPS (Basic)
2.83
1.59
3.15
5.07
6.75
6.03
Basic Shares Outstanding
15,415.40
33,667.00
37,429.30
39,126.40
46,587.60
57,418.30
EPS (Diluted)
2.83
1.59
3.15
5.07
6.75
6.03
Diluted Shares Outstanding
15,415.40
33,667.00
37,429.30
39,126.40
46,587.60
57,418.30
EBITDA
37,443.00
52,766.00
115,358.00
195,277.00
314,362.00
355,307
Non-Operating Interest Income
55.00
203.00
968.00
2,514.00
6,124.00
16,451
Preferred Dividends
4,162.00
-
-
-
-
-

About Agios Pharmaceuticals

View Profile
Address
88 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.agios.com
Updated 07/08/2019
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Its product candidates include IDHIFA, ivosidenib, AG-881, AG-348, and AG-270.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.